Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Theravance Biopharma, Inc. TBPH
$11.21
+$0.12 (1.08%)
На 18:00, 12 мая 2023
+24.89%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
694533216.00000000
-
week52high
12.03
-
week52low
7.53
-
Revenue
51346000
-
P/E TTM
1
-
Beta
0.50103800
-
EPS
-1.31000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Underweight | Underweight | 25 июл 2022 г. |
| SVB Leerink | Outperform | 23 мая 2022 г. | |
| Morgan Stanley | Underweight | Underweight | 02 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 24 февр 2022 г. |
| JP Morgan | Neutral | Underweight | 05 ноя 2021 г. |
| SVB Leerink | Outperform | Outperform | 17 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 08 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Winningham Rick E | D | 1350797 | 50000 | 14 дек 2022 г. |
| Winningham Rick E | D | 1400797 | 9000 | 13 дек 2022 г. |
| GRAHAM RICHARD A | D | 313520 | 2084 | 01 дек 2022 г. |
| O'Connor Donal | D | 43886 | 10000 | 22 ноя 2022 г. |
| Hindman Andrew A. | D | 384714 | 25057 | 20 ноя 2022 г. |
| Winningham Rick E | D | 1409797 | 15804 | 20 ноя 2022 г. |
| Farnum Rhonda | D | 296309 | 23268 | 20 ноя 2022 г. |
| GRAHAM RICHARD A | D | 315604 | 27350 | 20 ноя 2022 г. |
| Hindman Andrew A. | D | 409771 | 65000 | 18 ноя 2022 г. |
| GRAHAM RICHARD A | D | 342954 | 2800 | 16 ноя 2022 г. |
Новостная лента
Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return
Seeking Alpha
03 мая 2023 г. в 04:45
Theravance Biopharma has recently come under pressure from a reputable activist investor, Irenic Capital. The activist is pushing the company to initiate a large capital return and launch a strategic review.
Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023
PRNewsWire
24 апр 2023 г. в 06:00
DUBLIN , April 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2023 financial results and provide a business update after market close on Monday, May 8, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.
Theravance Biopharma to Participate in an Upcoming Investor Conference
PRNewsWire
10 апр 2023 г. в 06:00
DUBLIN , April 10, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17 at 3:45 pm ET (12:45 pm PT/8:45 pm IST).
Theravance Biopharma to Participate in an Upcoming Investor Conference
PRNewsWire
02 мар 2023 г. в 06:00
DUBLIN , March 2, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the 43rd Annual TD Cowen Health Care Conference on Wednesday, March 8 at 10:30 am ET (7:30 am PT/3:30 pm GMT). Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events.
Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates
Zacks Investment Research
28 февр 2023 г. в 15:49
Thervance's (TBPH) fourth-quarter loss wider than expected. Revenues decline year over year.